DRI Biosciences Corporation is developing proprietary and game-changing therapeutics to improve conditions of Fragile X Syndrome (FXS) and Autism Spectrum Disorder (ASD). FXS represents the most common form of inherited intellectual disability and is a frequent monogenic cause of autism. In the U.S. and Europe, there are more than 100,000 cases of FXS. Meanwhile, the total autistic incidence is approaching 2 million worldwide. The predicted therapeutic market is estimated at $5.5 billion by 2018, but there are no medications that effectively treat or improve these neurodevelopmental conditions.